Evidence map›Paper›PMID 33571507›Full record

ArticleHormones and behavior2021

Long-term oral administration of a novel estrogen receptor beta agonist enhances memory and alleviates drug-induced vasodilation in young ovariectomized mice.

Aaron W Fleischer, Jayson C Schalk, Edward A Wetzel, Alicia M Hanson, Daniel S Sem, William A Donaldson, Karyn M Frick

Open access · hybridAbstract read
In one paragraph

Article in Hormones and behavior, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Article
  3. The novel estrogen receptor beta agonist EGX358 andFrontiers in aging neuroscience · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Aaron W FleischerDepartment of Psychology, University of Wisconsin-Milwaukee, Milwaukee, WI 53211, United States of America. Electronic address: fleisc54@uwm.edu.
Jayson C SchalkDepartment of Psychology, University of Wisconsin-Milwaukee, Milwaukee, WI 53211, United States of America. Electronic address: jschalk3@huskers.unl.edu.
Edward A WetzelDepartment of Chemistry, Marquette University, Milwaukee, WI 53201-1881, United States of America. Electronic address: edward.wetzel@marquette.edu.
Alicia M HansonDepartment Pharmaceutical Sciences, Concordia University Wisconsin, Mequon, WI 53097, United States of America; Center for Structure-Based Drug Design and Development, Concordia University Wisconsin, Mequon, WI 53097, United States of America. Electronic address: alicia.schultz@cuw.edu.
Daniel S SemDepartment Pharmaceutical Sciences, Concordia University Wisconsin, Mequon, WI 53097, United States of America; Center for Structure-Based Drug Design and Development, Concordia University Wisconsin, Mequon, WI 53097, United States of America. Electronic address: daniel.sem@cuw.edu.
William A DonaldsonDepartment of Chemistry, Marquette University, Milwaukee, WI 53201-1881, United States of America. Electronic address: william.donaldson@marquette.edu.
Karyn M FrickDepartment of Psychology, University of Wisconsin-Milwaukee, Milwaukee, WI 53211, United States of America. Electronic address: frickk@uwm.edu.
University of Wisconsin–Milwaukee · USMarquette University · USConcordia University Wisconsin · USUniversity of Wisconsin System · US

Funding

Mechanisms underlying memory regulation by 17beta-estradiol, canonical Wnt signaling, and BDNF in male and female miceR01MH107886 · NIMH · UNIVERSITY OF WISCONSIN MILWAUKEE · PI FRICK, KARYN M · 2016 to 2020
$1.9M
Development of ER-beta Agonists to Treat Post-Menopausal Memory DeclineR15GM118304 · NIGMS · CONCORDIA UNIVERSITY WISCONSIN · PI SEM, DANIEL S · 2015 to 2018
$820k
NIGMS NIH HHS R15 GM118304NIMH NIH HHS R01 MH107886
6 · The paper itself

Abstract

Development of estrogen therapies targeting the β (ERβ) but not α (ERα) estrogen receptor is critically needed for the treatment of negative menopausal symptoms, as ERα activation increases health risks like cancer. Here, we determined the effects of long-term oral treatment with EGX358, a novel highly selective ERβ agonist, on memory, vasodilation, and affect in young ovariectomized mice. Mice were orally gavaged daily for 9 weeks with vehicle, 17β-estradiol (E

Indexed as

Estrogen Receptor betaPharmaceutical PreparationsAdministration, OralAnimalsEstradiolEstrogen Receptor alphaFemaleHumansMiceNitrilesOvariectomyVasodilationEstradiolEstrogen Receptor alphaEstrogen Receptor betaNitrilesPharmaceutical PreparationsAnxietyDepressionERβHot flashMenopauseMouseObject placementObject recognitionOvariectomy

Identifiers

PMID33571507
PMCPMC8680219
OpenAlexW3128431485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.